Gyre Therapeutics (GYRE) Expected to Announce Earnings on Tuesday

Gyre Therapeutics (NASDAQ:GYRE) is expected to be posting its Q4 2025 results before the market opens on Tuesday, March 31st. Analysts expect Gyre Therapeutics to post earnings of $0.06 per share and revenue of $36.3030 million for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:00 PM ET.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The firm had revenue of $37.20 million for the quarter, compared to the consensus estimate of $36.30 million. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%.

Gyre Therapeutics Trading Up 4.8%

Shares of NASDAQ:GYRE opened at $7.04 on Tuesday. Gyre Therapeutics has a 12 month low of $6.11 and a 12 month high of $11.78. The company has a market capitalization of $682.60 million, a price-to-earnings ratio of 704.70 and a beta of 1.97. The firm’s 50-day moving average is $7.92 and its 200 day moving average is $7.75.

Institutional Trading of Gyre Therapeutics

A number of hedge funds have recently bought and sold shares of GYRE. Geode Capital Management LLC increased its holdings in shares of Gyre Therapeutics by 28.6% in the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock valued at $2,953,000 after acquiring an additional 89,390 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of Gyre Therapeutics by 37.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after acquiring an additional 45,772 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Gyre Therapeutics during the 3rd quarter worth $267,000. State Street Corp lifted its stake in shares of Gyre Therapeutics by 10.7% during the 4th quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after purchasing an additional 19,472 shares during the last quarter. Finally, Lazard Asset Management LLC bought a new stake in Gyre Therapeutics during the third quarter valued at about $111,000. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on GYRE. Wall Street Zen lowered Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Weiss Ratings reiterated a “sell (d)” rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Finally, Zacks Research lowered Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $17.00.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.